UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 6)
| ImmunoGen,
Inc. |
| (Name of Issuer) |
| |
| Common Stock, $0.01 par value |
| (Title of Class of Securities) |
| December 31, 2023 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 45253H101
| 1 |
Name of Reporting Person
Redmile Group, LLC |
| 2 |
Check the Appropriate Box if
a Member of a Group (See Instructions)
(a) ¨
(b) ¨ |
| 3 |
SEC Use Only
|
| 4 |
Citizenship or Place of Organization
Delaware |
|
number
of
shares
beneficially
owned by
each
reporting
person with |
5 |
Sole Voting Power
0 |
| 6 |
Shared Voting Power
16,423,922 (1) |
| 7 |
Sole
Dispositive Power
0 |
| 8 |
Shared Dispositive Power
16,423,922 (1) |
| 9 |
Aggregate Amount Beneficially
Owned by Each Reporting Person
16,423,922 (1) |
| 10 |
Check if the Aggregate Amount
in Row (9) Excludes Certain Shares (See Instructions)
|
| 11 |
Percent of Class
Represented by Amount in Row (9)
5.9%(2) |
| 12 |
Type of Reporting Person (See
Instructions)
IA, OO |
| |
|
|
|
(1)
Redmile Group, LLC’s beneficial ownership of the Issuer’s
common stock (“Common Stock”) is comprised of 16,423,922 shares of Common Stock owned by certain private investment vehicles
and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group,
LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed
beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial
ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.
(2)
Percentage based on 279,354,016 shares of Common Stock outstanding
as of December 29, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed with the SEC on January 31, 2024 (the “Form
8-K”).
CUSIP No. 45253H101
| 1 |
Name of Reporting Person
Jeremy C. Green |
| 2 |
Check the Appropriate Box if
a Member of a Group (See Instructions)
(a) ¨
(b) ¨ |
| 3 |
SEC Use Only
|
|
4 |
Citizenship or Place of Organization
United Kingdom |
|
number
of
shares
beneficially
owned by
each
reporting
person with |
5 |
Sole Voting Power
0 |
| 6 |
Shared Voting Power
16,423,922 (3) |
| 7 |
Sole
Dispositive Power
0 |
| 8 |
Shared Dispositive Power
16,423,922 (3) |
| 9 |
Aggregate Amount Beneficially
Owned by Each Reporting Person
16,423,922 (3) |
| 10 |
Check if the Aggregate Amount
in Row (9) Excludes Certain Shares (See Instructions)
|
| 11 |
Percent of Class Represented
by Amount in Row (9)
5.9%(4) |
| 12 |
Type of Reporting Person (See
Instructions)
IN, HC |
| |
|
|
|
(3)
Jeremy C. Green’s beneficial ownership of Common Stock is comprised
of 16,423,922 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group,
LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment
vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal
of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its
or his pecuniary interest in such shares, if any.
(4)
Percentage based on 279,354,016 shares of Common Stock outstanding
as of December 29, 2023, as reported by the Issuer in the Form 8-K.
Item 1.
ImmunoGen, Inc.
| (b) | Address of Issuer’s Principal Executive Offices |
830 Winter Street
Waltham, MA 02451
Item 2.
| (a) | Names of Persons Filing |
Redmile Group, LLC
Jeremy C. Green
| (b) | Address of Principal Business office or, if None, Residence |
Redmile Group, LLC
One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129
Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001
Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom
| (d) | Title of Class of Securities |
Common Stock, $0.01 par value
45253H101
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
| (a) | ¨ |
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
| (b) | ¨ |
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
| (c) | ¨ |
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
| (d) | ¨ |
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); |
| (e) | x |
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
| (f) | ¨ |
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
| (g) | x |
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
| (h) | ¨ |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | ¨ |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a-3); |
| (j) | ¨ |
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); |
| (k) | ¨ |
Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance
with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________ |
| (a) | Amount beneficially owned: |
Redmile Group, LLC – 16,423,922 *
Jeremy C. Green – 16,423,922 *
Redmile Group, LLC – 5.9%**
Jeremy C. Green – 5.9%**
| (c) | Number of shares as to which Redmile Group, LLC has: |
| (i) | Sole power to vote or to direct the vote: |
0
| (ii) | Shared power to vote or to direct the vote: |
16,423,922 *
| (iii) | Sole power to dispose or to direct the disposition of: |
0
| (iv) | Shared power to dispose or to direct the disposition of: |
16,423,922 *
Number of shares as to which Jeremy C. Green has:
| (i) | Sole power to vote or to direct the vote: |
0
| (ii) | Shared power to vote or to direct the vote: |
16,423,922 *
| (iii) | Sole power to dispose or to direct the disposition of: |
0
| (iv) | Shared power to dispose or to direct the disposition of: |
16,423,922 *
| * | Redmile Group, LLC’s and
Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 16,423,922 shares of Common Stock owned
by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be
deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts.
The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group,
LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares,
if any. |
| ** | Percentage based on 279,354,016 shares of Common Stock outstanding
as of December 29, 2023, as reported by the Issuer in the Form 8-K |
| Item 5. | Ownership of Five Percent or Less of a Class. |
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than 5 percent of the class of securities, check the following ¨
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
N/A.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
or Control Person. |
See the response to Item 4.
| Item 8. | Identification and Classification of Members of the Group. |
N/A.
| Item 9. | Notice of Dissolution of Group. |
N/A.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in
connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 14, 2024
| |
Redmile Group, LLC
|
| |
|
|
| |
By: |
|
/s/ Jeremy C. Green |
| |
|
|
Name: Jeremy C. Green
Title: Managing Member |
| |
|
|
/s/ Jeremy C. Green |
| |
|
|
Jeremy C. Green |
Exhibit 99.1
Joint Filing Agreement
In accordance with Rule 13d-1(k)(1)
under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint
filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”)
relating to the Common Stock, $0.01 par value per share, of ImmunoGen, Inc., which may be deemed necessary pursuant to Regulation 13D
or 13G promulgated under the Exchange Act.
The undersigned further agree
that each party hereto is responsible for the timely filing of the Schedule 13G, and for the accuracy and completeness of the information
concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information
concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate.
It is understood and agreed
that a copy of this Joint Filing Agreement shall be attached as an exhibit to the Schedule 13G, filed on behalf of each of the parties
hereto.
IN WITNESS WHEREOF,
each of the undersigned has executed this Joint Filing Agreement as of the 14th day of February, 2024.
| |
REDMILE GROUP, LLC |
| |
|
| |
|
| |
/s/ Jeremy C. Green |
| |
Name: Jeremy C. Green |
| |
Title: Managing Member |
| |
|
| |
|
| |
|
| |
/s/ Jeremy C. Green |
| |
JEREMY
C. Green |
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Nov 2023 a Nov 2024
